A 52-week, Open Phase III Study Evaluating the Long-term Safety and Efficacy of HSK16149 Capsules in Chinese Patients With Peripheral Neuralgia
Latest Information Update: 06 Oct 2025
At a glance
- Drugs Crisugabalin (Primary)
- Indications Neuralgia
- Focus Adverse reactions; Registrational
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 04 Sep 2025 Status changed from active, no longer recruiting to completed.
- 09 Jun 2023 New trial record